Tags

Type your tag names separated by a space and hit enter

Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen).
Hum Vaccin. 2011 May; 7(5):563-8.HV

Abstract

Post-hoc analyses of the Rotavirus Efficacy and Safety Trial (REST) were conducted to determine whether the pentavalent rotavirus vaccine (RV5) confers early protection against rotavirus gastroenteritis (RVGE) before completion of the 3-dose regimen. To evaluate the efficacy of RV5 between doses in reducing the rates of RVGE-related hospitalizations and emergency department (ED) visits in infants who ultimately received all 3 doses of RV5/placebo, events occurring from 2 weeks after the first and second doses to receipt of the subsequent dose (Analysis A) and events occurring from 2 weeks after the first and second doses to 2 weeks after the subsequent dose (Analysis B) were analyzed. In Analysis A, RV5 reduced the rates of combined hospitalizations and ED visits for G1-G4 RVGE or RVGE regardless of serotype between doses 1 and 2 by 100% (95% confidence interval [CI]: 72-100%) or 82% (95% CI: 39-97%), respectively, and between doses 2 and 3, RV5 reduced the rates of combined hospitalizations and ED visits for G1-G4 RVGE or RVGE regardless of serotype by 91% (95% CI: 63-99%) or 84% (95% CI: 54-96%), respectively. Similar rate reductions were observed in Analysis B. These data suggest that RV5 provides a high level of protection between doses against hospitalizations and ED visits for RVGE starting as early as 14 days after the first dose.

Authors+Show Affiliations

The Alpert Medical School of Brown University and Hasbro Children's Hospital, Providence, RI, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

21441783

Citation

Dennehy, Penelope H., et al. "Efficacy of the Pentavalent Rotavirus Vaccine, RotaTeq® (RV5), Between Doses of a 3-dose Series and With Less Than 3 Doses (incomplete Regimen)." Human Vaccines, vol. 7, no. 5, 2011, pp. 563-8.
Dennehy PH, Vesikari T, Matson DO, et al. Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen). Hum Vaccin. 2011;7(5):563-8.
Dennehy, P. H., Vesikari, T., Matson, D. O., Itzler, R. F., Dallas, M. J., Goveia, M. G., DiNubile, M. J., Heaton, P. M., & Ciarlet, M. (2011). Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen). Human Vaccines, 7(5), 563-8.
Dennehy PH, et al. Efficacy of the Pentavalent Rotavirus Vaccine, RotaTeq® (RV5), Between Doses of a 3-dose Series and With Less Than 3 Doses (incomplete Regimen). Hum Vaccin. 2011;7(5):563-8. PubMed PMID: 21441783.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen). AU - Dennehy,Penelope H, AU - Vesikari,Timo, AU - Matson,David O, AU - Itzler,Robbin F, AU - Dallas,Michael J, AU - Goveia,Michelle G, AU - DiNubile,Mark J, AU - Heaton,Penny M, AU - Ciarlet,Max, Y1 - 2011/05/01/ PY - 2011/3/29/entrez PY - 2011/3/29/pubmed PY - 2011/12/17/medline SP - 563 EP - 8 JF - Human vaccines JO - Hum Vaccin VL - 7 IS - 5 N2 - Post-hoc analyses of the Rotavirus Efficacy and Safety Trial (REST) were conducted to determine whether the pentavalent rotavirus vaccine (RV5) confers early protection against rotavirus gastroenteritis (RVGE) before completion of the 3-dose regimen. To evaluate the efficacy of RV5 between doses in reducing the rates of RVGE-related hospitalizations and emergency department (ED) visits in infants who ultimately received all 3 doses of RV5/placebo, events occurring from 2 weeks after the first and second doses to receipt of the subsequent dose (Analysis A) and events occurring from 2 weeks after the first and second doses to 2 weeks after the subsequent dose (Analysis B) were analyzed. In Analysis A, RV5 reduced the rates of combined hospitalizations and ED visits for G1-G4 RVGE or RVGE regardless of serotype between doses 1 and 2 by 100% (95% confidence interval [CI]: 72-100%) or 82% (95% CI: 39-97%), respectively, and between doses 2 and 3, RV5 reduced the rates of combined hospitalizations and ED visits for G1-G4 RVGE or RVGE regardless of serotype by 91% (95% CI: 63-99%) or 84% (95% CI: 54-96%), respectively. Similar rate reductions were observed in Analysis B. These data suggest that RV5 provides a high level of protection between doses against hospitalizations and ED visits for RVGE starting as early as 14 days after the first dose. SN - 1554-8619 UR - https://www.unboundmedicine.com/medline/citation/21441783/Efficacy_of_the_pentavalent_rotavirus_vaccine_RotaTeq®__RV5__between_doses_of_a_3_dose_series_and_with_less_than_3_doses__incomplete_regimen__ L2 - http://www.tandfonline.com/doi/full/10.4161/hv.7.5.15406 DB - PRIME DP - Unbound Medicine ER -